tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CDTX Stock Latest News

Promising Phase 2b Results for Cidara’s CD388 Justify Buy Rating Amidst Strong Preventive Efficacy Against Influenza
RatingsPromising Phase 2b Results for Cidara’s CD388 Justify Buy Rating Amidst Strong Preventive Efficacy Against Influenza
7h ago
CDTX
Cidara Therapeutics announces Phase 2b presentation on CD388 at ID Week 2025
PremiumThe Fly
Cidara Therapeutics announces Phase 2b presentation on CD388 at ID Week 2025
11h ago
CDTX
Cidara Therapeutics initiated with an Overweight at Morgan Stanley
PremiumThe Fly
Cidara Therapeutics initiated with an Overweight at Morgan Stanley
6d ago
CDTX
Buy Rating for Cidara Therapeutics: Promising Antiviral CD388 Targets $5 Billion Influenza Market
PremiumRatings
Buy Rating for Cidara Therapeutics: Promising Antiviral CD388 Targets $5 Billion Influenza Market
6d ago
CDTX
Align downgraded, NetEase upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Align downgraded, NetEase upgraded: Wall Street’s top analyst calls
11d ago
ABT
MOS
Cidara Therapeutics initiated with an Overweight at JPMorgan
PremiumThe FlyCidara Therapeutics initiated with an Overweight at JPMorgan
12d ago
CDTX
Cidara Therapeutics: Strategic Advancements and Financial Strength Bolster Buy Rating
Premium
Ratings
Cidara Therapeutics: Strategic Advancements and Financial Strength Bolster Buy Rating
12d ago
CDTX
Cidara Therapeutics price target raised to $150 from $110 at H.C. Wainwright
Premium
The Fly
Cidara Therapeutics price target raised to $150 from $110 at H.C. Wainwright
12d ago
CDTX
Cidara Therapeutics: Strong Buy Rating Backed by Breakthrough Therapy Designation and Promising CD388 Efficacy
PremiumRatings
Cidara Therapeutics: Strong Buy Rating Backed by Breakthrough Therapy Designation and Promising CD388 Efficacy
12d ago
CDTX
Cidara Therapeutics receives U.S. FDA BTD for CD388
PremiumThe Fly
Cidara Therapeutics receives U.S. FDA BTD for CD388
12d ago
CDTX
Cidara Therapeutics price target raised to $173 from $153 at Citizens JMP
PremiumThe Fly
Cidara Therapeutics price target raised to $173 from $153 at Citizens JMP
19d ago
CDTX
Closing Bell Movers: Rumble jumps 11% on Perplexity partnership
PremiumThe Fly
Closing Bell Movers: Rumble jumps 11% on Perplexity partnership
19d ago
CF
CLS
Cidara Therapeutics announces $339M BARDA award
PremiumThe FlyCidara Therapeutics announces $339M BARDA award
19d ago
CDTX
Cidara Therapeutics price target raised to $110 from $74 at H.C. Wainwright
Premium
The Fly
Cidara Therapeutics price target raised to $110 from $74 at H.C. Wainwright
26d ago
CDTX
Cidara Therapeutics doses first patient in CD388 trial
Premium
The Fly
Cidara Therapeutics doses first patient in CD388 trial
26d ago
CDTX
Cidara Therapeutics Expands Phase 3 Trial for CD388
PremiumCompany Announcements
Cidara Therapeutics Expands Phase 3 Trial for CD388
27d ago
8K
CDTX
Cidara Therapeutics price target raised to $153 from $66 at Citizens JMP
PremiumThe Fly
Cidara Therapeutics price target raised to $153 from $66 at Citizens JMP
27d ago
CDTX
Cidara Therapeutics price target raised to $100 from $74 at Needham
PremiumThe Fly
Cidara Therapeutics price target raised to $100 from $74 at Needham
27d ago
CDTX
Cidara Therapeutics’ Accelerated Path to BLA Approval and Expanded Market Potential Boosts Buy Rating
PremiumRatings
Cidara Therapeutics’ Accelerated Path to BLA Approval and Expanded Market Potential Boosts Buy Rating
27d ago
CDTX
Accelerated Phase 3 Study and Expanded Market Potential Make Cidara Therapeutics a Strong Buy
PremiumRatingsAccelerated Phase 3 Study and Expanded Market Potential Make Cidara Therapeutics a Strong Buy
27d ago
CDTX
Cidara Therapeutics price target raised to $167 from $70 at Guggenheim
Premium
The Fly
Cidara Therapeutics price target raised to $167 from $70 at Guggenheim
27d ago
CDTX
Cidara announced several positive CD388 updates, says H.C. Wainwright
Premium
The Fly
Cidara announced several positive CD388 updates, says H.C. Wainwright
27d ago
CDTX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >